Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2018's ADA Standards of Care update. 

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2017's ADA Standards of Care update. 

Sanjay Kalra, Diabetologist and Editorial Board member, outlines what's new in the American Diabetes Association’s 2020 Standards of Care update. 

Munter P et al. Diabetes Care 2018: dc181307. doi: 10.2337/dc18-1307

Chiang JL et al. Diabetes Care 2018: dci180023. doi: 10.2337/dci18-0023

The ADA Presidents Oral Session closed the 2017 American Diabetes Association 77th Scientific Sessions.

Guidelines, specifically those from the International Diabetes Federation [11] and the American Diabetes Association (ADA) Standards of Care [12], address the issues of treatment targets in older adults and acknowledge the risks associated with intensive management.

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

What's new in the 2019 update to the ADA guidelines on nutrition therapy for adults with diabetes or prediabetes? Diabetes Educator Amy Hess Fischl explains.

Symposia on the second day of the 2017 American Diabetes Association 77th Scientific Sessions focused on topics ranging from the mechanistic links between cancer, obesity, and diabetes to novel islet signaling pathways and dealing with the rising costs of insulin.

The opening day of the 2017 American Diabetes Association 77th Scientific Sessions featured symposia on a broad range of topics including the stigma of diabetes, management of diabetic neuropathy, biomarkers of type 1 diabetes, and the role of the intestinal immune system in metabolic disease.

Symposia on the penultimate day of the 2017 American Diabetes Association 77th Scientific Sessions looked at, among other things, healthy lifestyle matters for patients with diabetes and kidney disease, preserving the beta-cell function, and systemic correlates of diabetic retinopathy.

Data from the ODYSSEY series of trials, presented at the American Diabetes Association scientific sessions, show that the PCSK9 inhibitor alirocumab reduces atherogenic dyslipidemia in patients with diabetes.

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Jay Shubrook explores why it is so important to include hypoglycemia assessment and management as part of your diabetes management plan.

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

Most research shows a U-shaped association, with both excessively short and overly long sleep durations increasing diabetes risk.

The recent joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) favors dipeptidyl peptidase-4 (DPP-4) inhibitors over sulfonylureas as second- or third-line therapy in type 2 diabetes management.